Status:

COMPLETED

A Skin Irritation Assessment of Once-Weekly Corplex™ Donepezil Transdermal Delivery System

Lead Sponsor:

Corium, Inc.

Conditions:

Skin Irritation

Sensitization

Eligibility:

All Genders

40+ years

Phase:

PHASE1

Brief Summary

A study to assess the skin irritation and sensitization potential of Corplex™ Donepezil Transdermal Delivery System (TDS)

Detailed Description

This study is a multiple center, randomized, double-blind, vehicle-controlled, and multiple-dose study to assess skin irritation and skin sensitization in healthy subjects. Subjects will be randomize...

Eligibility Criteria

Inclusion

  • Healthy, adult, male or female
  • Body mass index ≥ 18.0 and ≤ 35.0 kg/m2
  • Medically healthy, as deemed by the Investigator
  • Have a skin type with Fitzpatrick scale score of I, II, or III

Exclusion

  • History or presence of alcoholism or drug abuse
  • History or presence of hypersensitivity or idiosyncratic reaction to the study product or related compounds
  • Positive urine drug or alcohol results
  • Female subjects with a positive pregnancy test or who are lactating
  • Any of the following drugs, but not limited to, for 30 days prior to the first dose of study product treatment on Day 1 and throughout the study:
  • Inducers of cytochrome enzymes and/or P-glycoprotein
  • Anti-inflammatory drugs or cyclooxygenase 2 analgesics
  • Beta-blockers
  • Cholinergics and anticholinergics
  • Muscle relaxants, anti-Parkinsonian, or neuroleptic medications
  • History or presence of significant skin damage deemed by the investigator to potentially interfere
  • Any medical or surgical procedure or trauma
  • Participation in another clinical study within 30 days or 5 times the half-life of the investigational product (whichever is longer) prior to the first study product treatment

Key Trial Info

Start Date :

November 14 2017

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

April 2 2018

Estimated Enrollment :

256 Patients enrolled

Trial Details

Trial ID

NCT03397862

Start Date

November 14 2017

End Date

April 2 2018

Last Update

September 14 2018

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

Celerion Inc.

Phoenix, Arizona, United States, 85283

2

Celerion Inc.

Lincoln, Nebraska, United States, 68502